Ovarian cancer prevention by opportunistic salpingectomy is a new de facto standard in Germany.
Cancer prevention
Case number analysis
Definitive contraception
Fallopian tubes
Hysterectomy
Opinion
Opportunistic salpingectomy
Tubal sterilization
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
16
12
2022
accepted:
06
01
2023
medline:
31
7
2023
pubmed:
28
2
2023
entrez:
27
2
2023
Statut:
ppublish
Résumé
The most prevalent and aggressive subtype of epithelial ovarian carcinoma (EOC), high-grade serous carcinoma (HGSC), originates in many cases from the fallopian tubes. Because of poor prognosis and lack of effective screening for early detection, opportunistic salpingectomy (OS) for prevention of EOC is being implemented into clinical routine in several countries worldwide. Taking the opportunity of a gynecological surgery in women at average cancer risk, extramural fallopian tubes are completely resected preserving the ovaries with their infundibulopelvic blood supply. Until recently, only 13 of the 130 national partner societies of the International Federation of Obstetrics and Gynecology (FIGO) have published a statement on OS. This study aimed to analyze the acceptance of OS in Germany. (1) Survey of German gynecologists in 2015 and 2022 by the Department of Gynecology of the Jena University Hospital in co-operation with the Department of Gynecology at Charité-University Medicine Berlin with support of NOGGO e. V. and AGO e. V. (2) Salpingectomy numbers in Germany for years 2005-2020 as retrieved from the Federal Statistical Office of Germany (Destatis). (1) Survey: Number of participants was 203 in 2015 and 166 in 2022, respectively. Nearly all respondents (2015: 92%, 2022: 98%) have already performed bilateral salpingectomy without oophorectomy in combination with benign hysterectomy with the intention to reduce the risk for malignant (2015: 96%, 2022: 97%) and benign (2015: 47%, 2022: 38%) disorders. Compared to 2015 (56.6%), considerably more survey participants performed OS in > 50% or in all cases in 2022 (89.0%). Recommendation of OS for all women with completed family planning at benign pelvic surgery was approved by 68% in 2015 and 74% in 2022. (2) Case number analysis: In 2020, four times more cases of salpingectomy were reported by German public hospitals compared to 2005 (n = 50,398 vs. n = 12,286). Of all inpatient hysterectomies in German hospitals in 2020, 45% were combined with salpingectomy, and more than 65% in women at the age of 35 to 49 years. Mounting scientific plausibility regarding involvement of fallopian tubes in the pathogenesis of EOC led to change of clinical acceptance of OS in many countries including in Germany. Case number data and widespread expert judgment demonstrate that OS has become a routine procedure in Germany and a de facto standard for primary prevention of EOC.
Identifiants
pubmed: 36847838
doi: 10.1007/s00432-023-04578-5
pii: 10.1007/s00432-023-04578-5
pmc: PMC10374707
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6953-6966Informations de copyright
© 2023. The Author(s).
Références
Eur J Cancer. 2021 Mar;145:38-43
pubmed: 33418235
Histopathology. 2022 Apr;80(5):762-778
pubmed: 34996131
Front Oncol. 2022 Aug 31;12:951292
pubmed: 36119503
Hum Reprod. 2021 Jan 1;36(1):211-218
pubmed: 33156914
BMJ Open. 2013 Jun 20;3(6):
pubmed: 23794553
Am J Surg Pathol. 2010 Mar;34(3):433-43
pubmed: 20154587
Arch Gynecol Obstet. 2018 Dec;298(6):1131-1137
pubmed: 30306309
J Res Med Sci. 2017 May 30;22:68
pubmed: 28616055
Am J Obstet Gynecol. 2020 Nov;223(5):721.e1-721.e18
pubmed: 32360846
Gynecol Oncol. 2019 Jan;152(1):127-132
pubmed: 30477808
Acta Obstet Gynecol Scand. 2015 Jan;94(1):86-94
pubmed: 25256594
J Ovarian Res. 2021 Jun 29;14(1):86
pubmed: 34187523
JAMA Netw Open. 2022 Feb 1;5(2):e2147343
pubmed: 35138400
Gynecol Oncol. 2014 Dec;135(3):423-7
pubmed: 25316178
J Minim Invasive Gynecol. 2017 May - Jun;24(4):563-578
pubmed: 28223181
Gynecol Oncol. 2017 Aug;146(2):373-379
pubmed: 28577884
Am J Surg Pathol. 2007 Feb;31(2):161-9
pubmed: 17255760
J Pathol. 2001 Nov;195(4):451-6
pubmed: 11745677
Maturitas. 2022 May;159:62-68
pubmed: 35337614
Am J Surg Pathol. 2006 Feb;30(2):230-6
pubmed: 16434898
J Clin Oncol. 2008 Sep 1;26(25):4160-5
pubmed: 18757330
Am J Obstet Gynecol. 2021 Oct;225(4):397.e1-397.e6
pubmed: 33798477
Am J Surg Pathol. 2011 Nov;35(11):1605-14
pubmed: 21997682
Cochrane Database Syst Rev. 2019 Aug 28;8:CD012858
pubmed: 31456223
Am J Obstet Gynecol. 2021 Mar;224(3):258-265.e4
pubmed: 32941790
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 May;56(5-6):716-22
pubmed: 23703490
Dtsch Arztebl Int. 2022 Dec 9;119(49):846-847
pubmed: 36814422
Hum Reprod Update. 2011 Jan-Feb;17(1):55-67
pubmed: 20634209
J Obstet Gynaecol Can. 2022 Nov;44(11):1174-1180
pubmed: 36099965
Int J Cancer. 2021 Oct 15;149(8):1544-1552
pubmed: 34152012
Clin Oncol (R Coll Radiol). 2018 Aug;30(8):463-471
pubmed: 29691126
J Cancer Res Ther. 2018 Apr-Jun;14(3):543-548
pubmed: 29893313
Arch Gynecol Obstet. 2015 Jul;292(1):231-4
pubmed: 25914073
JSLS. 2018 Jul-Sep;22(3):
pubmed: 30275673
Am J Obstet Gynecol. 2016 Nov;215(5):666-667
pubmed: 27498310
J Minim Invasive Gynecol. 2013 Jul-Aug;20(4):517-21
pubmed: 23870241
Eur J Obstet Gynecol Reprod Biol. 2018 Jun;225:110-112
pubmed: 29704813
J Cancer Res Clin Oncol. 2014 May;140(5):859-65
pubmed: 24573653
Cancer Prev Res (Phila). 2021 Dec;14(12):1101-1110
pubmed: 34413116
Int J Gynecol Pathol. 2009 Jul;28(4):308-15
pubmed: 19483636
Nat Commun. 2017 Oct 23;8(1):1093
pubmed: 29061967
J Natl Cancer Inst. 2015 Jan 27;107(2):
pubmed: 25628372
Maturitas. 2022 Aug 17;166:21-34
pubmed: 36030627
Geburtshilfe Frauenheilkd. 2016 Dec;76(12):1325-1329
pubmed: 28017973